Wansheng Ma; Wenzhao Liu; Junyu Mu

doi:10.14715/cmb/2023.69.3.16

Issue

Vol. 69 No. 3: Issue 3

Issue Published : June 10, 2023

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Influencing Mechanism of Large-dose of Atorvastatin in Serum Visfatin, MMP-9, and Blood Fat Levels of Patients with Acute Coronary Syndromes

Large-dose of Atorvastatin in Serum Visfatin, MMP-9 and Blood Fat

https://doi.org/10.14715/cmb/2023.69.3.16

Wansheng Ma

Department of Cardiology, Qingdao Municipal Hospital, Qingdao 266071, Shandong Province, China

Wenzhao Liu

Cadre Health Section, Qingdao Municipal Hospital (West Hospital District), Dry Care Department of Qingdao Municipal Hospital (West Hospital District), Qingdao 266011, Shandong Province, China

Junyu Mu

Department of Cardiology, Qingdao Municipal Hospital, Qingdao 266071, Shandong Province, China

Corresponding Author(s) : Wansheng Ma

qujiao7617539960@163.com

Cellular and Molecular Biology, Vol. 69 No. 3: Issue 3
Article Published : March 31, 2023

Abstract

The research was conducted to analyze the clinical effects and corresponding molecular mechanisms of short-term treatment of acute coronary syndromes (ACS) by different doses of atorvastatin. In the research, a total of 90 ACS patients were included as the samples and divided into an experimental group (conventional treatment+60mg/per time/late atorvastatin), control group 1 (conventional treatment+25mg/per time/late atorvastatin), and control group 2 (25mg/per time/late atorvastatin) according to different doses of atorvastatin. After that, their blood fat and inflammatory factors before and after treatment were analyzed. Total cholesterol (TC) and high-density liptein cholesterol (HDL-C) levels of the experimental group were inferior to those of control groups 1 and 2 in the 5^th and 7^th days (P<0.05). After treatment, visfatin, matrix metalloproteinase-9 (MMP-9), and brain natriuretic peptide (BNP) of patients in the experimental group and control groups 1 and 2 were notably inferior to those in control groups 1 and 2 (P<0.05). Besides, interleukin-6 (IL-6) and hypersensitive C-reactive protein (hs-CRP) of patients in the experimental group and control groups 1 and 2 were inferior to those in control groups 1 and 2 after treatment (P<0.05). Based on the above results, the short-term treatment by large-dose atorvastatin could reduce blood far and inflammatory factor levels of ACS patients more effectively than by conventional dose, and further inhibit inflammatory reactions and improve patient prognosis with safety and feasibility.

Keywords

atorvastatin short-term treatment acute coronary syndromes blood fat level inflammatory reactions serum visfatin

Ma, W., Liu, W., & Mu, J. (2023). Influencing Mechanism of Large-dose of Atorvastatin in Serum Visfatin, MMP-9, and Blood Fat Levels of Patients with Acute Coronary Syndromes: Large-dose of Atorvastatin in Serum Visfatin, MMP-9 and Blood Fat . Cellular and Molecular Biology, 69(3), 118–123. https://doi.org/10.14715/cmb/2023.69.3.16